Floatz logo

296 assets in Myelodysplastic Syndrome

Therapeutic assets addressing Myelodysplastic Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
cc-91633
Myelodysplastic Syndrome
CelgeneP1C (37)
cd33 fpbmc
Myelodysplastic Syndrome
University of VirginiaP1C (37)
cd4+cd25+ regulatory t cells
Myelodysplastic Syndrome
Stanford UniversityP1C (37)
Ciml-Nk Cells
Myelodysplastic Syndrome
Dana-Farber Cancer InstituteP1C (37)
Cytokine Induced Memory-Like Natural Killer Cells
Myelodysplastic Syndrome
Dana-Farber Cancer InstituteP1C (37)
Danvatirsen
Myelodysplastic Syndrome
Montefiore Medical CenterP1C (37)
Defactinib
Myelodysplastic Syndrome
Clinical Hub for Interventional Research (CHOIR)P1C (37)
dsp107
Myelodysplastic Syndrome
Kahr MedicalP1C (37)
Eagd T-Cell Infusion
Myelodysplastic Syndrome
University of Kansas Medical CenterP1C (37)
fxs0683
Myelodysplastic Syndrome
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.P1C (37)
Glb-001
Myelodysplastic Syndrome
Hangzhou GluBio Pharmaceutical Co., Ltd.P1C (37)
Gtb-360
Myelodysplastic Syndrome
Masonic Cancer Center, University of MinnesotaP1C (37)
Immunoglobulin G4, Anti-(Human Cd3 Antigen) (Recombinant Human Monoclonal Jnj-75348780 ?4-Chain), Disulfide With Recombinant Human Monoclonal Jnj-75348780 ? Chain, (229?126?),(232?129?)-Bis(Disulfide) With Immunoglobulin, Anti-(Human Sialic Acid-Binding Ig-Like Lectin 2) (Recombinant Human Single-Domain Vhh Fragment)
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-54179060
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-64264681
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-70218902
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-80948543
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
Jnj-87801493
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
lp-108
Myelodysplastic Syndrome
Guangzhou Lupeng Pharmaceutical Company LTD.P1C (37)
mgd024
Myelodysplastic Syndrome
MacroGenicsP1C (37)
Orcagraft
Myelodysplastic Syndrome
Orca Biosystems, Inc.P1C (37)
Prgn-3006 T Cells
Myelodysplastic Syndrome
Precigen, IncP1C (37)
Rem-422
Myelodysplastic Syndrome
Remix TherapeuticsP1C (37)
Sabatolimab
Myelodysplastic Syndrome
Novartis PharmaceuticalsP1/2C (37)
Safimaltib
Myelodysplastic Syndrome
Janssen Research & Development, LLCP1C (37)
sl-172154
Myelodysplastic Syndrome
Shattuck Labs, Inc.P1C (37)
Sprx002
Myelodysplastic Syndrome
Arcellx, Inc.P1C (37)
tqb2928
Myelodysplastic Syndrome
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P1C (37)
Treg-Enriched Donor Cell
Myelodysplastic Syndrome
Dana-Farber Cancer InstituteP1C (37)
trx103
Myelodysplastic Syndrome
Tr1X, Inc.P1C (37)
Tsc-100
Myelodysplastic Syndrome
TScan Therapeutics, Inc.P1C (37)
Tsc-101
Myelodysplastic Syndrome
TScan Therapeutics, Inc.P1C (37)
Vactosertib
Myelodysplastic Syndrome
David WaldP1C (37)
Tagraxofusp-Erzs
Myelodysplastic Syndrome
City of Hope Medical CenterP1D (30)
Autx-703
Myelodysplastic Syndrome
Auron Therapeutics, Inc.P1NR ()
azd3632
Myelodysplastic Syndrome
AstraZenecaP1/2NR ()
bh-30236
Myelodysplastic Syndrome
BlossomHill TherapeuticsP1NR ()
Byon4413
Myelodysplastic Syndrome
Byondis B.V.P1NR ()
gen3018
Myelodysplastic Syndrome
GenmabP1NR ()
lp-118
Myelodysplastic Syndrome
Newave Pharmaceutical IncP1NR ()
nc525
Myelodysplastic Syndrome
NextCure, Inc.P1NR ()
Sgr-2921
Myelodysplastic Syndrome
Schrödinger, Inc.P1NR ()
Showing 251 to 296 of 296 assets
PreviousPage 6 of 6Next